Global Viral Vectors, Non-Viral Vectors & Gene Therapy Manufacturing Industry Outlook (2019-2030): Focus on Contract Manufacturers & Companies with In-house Manufacturing Facilities – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)” report has been added to ResearchAndMarkets.com’s offering.

This report features an extensive study of the rapidly growing market of viral and non-viral vector and gene therapy manufacturing, focusing on contract manufacturers, as well as companies with in-house manufacturing facilities. The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different regions of the globe.

At present, 10+ genetically modified therapies have received approval / conditional approval in various regions of the world; these include (in the reverse chronological order of year of approval) Zynteglo (2019), Zolgensma (2019), Collategene (2019), LUXTURNA (2017), YESCARTA (2017), Kymriah (2017), INVOSSA (2017), Zalmoxis (2016), Strimvelis (2016), Imlygic (2015), Neovasculagen (2011), Rexin-G (2007), Oncorine (2005) and Gendicine (2003). In addition, over 500 therapy candidates are being investigated across different stages of development. The growing number of gene-based therapies, coupled to their rapid progression through the drug development process, has created significant opportunities for companies with expertise in vector manufacturing.

Presently, a number of industry (including both well-established companies and smaller R&D-focused initiatives), and non-industry players (academic institutes) claim to be capable of manufacturing different types of viral and non-viral vectors. In addition, there are several players offering novel technology solutions, which are capable of improving existing genetically modified therapy products and upgrading their affiliated manufacturing processes.

Considering prevalent and anticipated future trends, we believe that the vector and gene therapy manufacturing market is poised to grow steadily, driven by a robust pipeline of therapy candidates and technical advances aimed at mitigating existing challenges related to gene delivery vector and advanced therapy medicinal products.

Scope of the Report

• An overview of the current status of the market with respect to the players involved (both industry and non-industry) in manufacturing viral vectors, non-viral vectors and other novel types of vectors. It features information on the year of establishment, scale of production, type of vectors manufactured, location of manufacturing facilities, applications of vectors (in gene therapy, cell therapy, vaccines and others), and purpose of production (fulfilling in-house requirements / for contract services).
• An informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies; the analysis also takes into consideration various relevant parameters, such as target patient population, dosing frequency, and dose strength.
• An estimate of the overall, installed vector manufacturing capacity of industry players based on information available in the public domain, and insights generated via both secondary and primary research. The analysis also highlights the distribution of the global capacity by vector type (viral vector and plasmid DNA), scale of operation (clinical and commercial), size of the company / organization (small-sized, mid-sized and large) and key geographical regions (North America, Europe, Asia Pacific and the rest of the world).
• An in-depth analysis of viral vector and plasmid DNA manufacturers, featuring three schematic representations; namely [A] a three dimensional grid analysis, representing the distribution of vector manufacturers (on the basis of type of vector) across various scales of operation and purpose of production (in-house operations and contract manufacturing services), [B] a logo landscape of viral vector and plasmid DNA manufacturers based on the type (industry and non-industry) and the size of the industry player (small-sized, mid-sized and large companies), and [C] a schematic world map representation, highlighting the geographical locations of vector manufacturing hubs.
• An analysis of recent collaborations and partnership agreements inked in this domain since 2015; it includes details of deals that were/are focused on the manufacturing of vectors, which were analyzed on the basis of year of agreement, type of agreement, type of vector involved, and scale of operation (laboratory, clinical and commercial).
• An analysis of the various factors that are likely to influence the pricing of vectors, featuring different models/approaches that may be adopted by product developers/manufacturers in order to decide the prices of proprietary vectors.
• An overview of other viral / non-viral gene delivery approaches that are currently being researched for the development of therapies involving genetic modification.
• Elaborate profiles of key players based in North America, Europe and Asia-Pacific (shortlisted based on scale of operation). Each profile features an overview of the company/organization, its financial performance (if available), information on its manufacturing facilities, vector manufacturing technology and an informed future outlook.
• A discussion on the factors driving the market and the various challenges associated with the vector production process.

Key Topics Covered

1. Preface

2. Executive Summary

3. Introduction

4. Viral Vector and Gene Therapy Manufacturers (Industry Players): Competitive Landscape

5. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Competitive Landscape

6. Vector and Gene Therapy Manufacturers (Non-Industry Players): Competitive Landscape

7. Vector and Gene Therapy Manufacturers in North America

8. Vector and Gene Therapy Manufacturers in Europe

9. Vector and Gene Therapy Manufacturers in Asia-Pacific

10. Emerging Vectors

11. Recent Collaborations and Partnerships

12. Key Insights

13. Viral Vector and Plasmid DNA Cost Price Analysis

14. Capacity Analysis

15. Demand Analysis

16. Market Sizing and Opportunity Analysis

17. Key Drivers and Challenges

18. Survey Analysis

19. Concluding Remarks

20. Executive Insights

21. Appendix I: Tabulated Data

22. Appendix II: List of Companies and Organizations

Companies Mentioned

• 4D Molecular Therapeutics
• AbbVie
• Abeona Therapeutics
• Acucela
• Adaptimmune Therapeutics
• Addgene
• Aduro Biotech
• Advanced BioScience Laboratories (ABL)
• Advanced Biotherapeutics Consulting
• Advaxis
• ADVENT
• Adverum Biotechnologies (previously known as Avalanche Biotechnologies)
• Agenzia Italiana del Farmaco
• Agilent Technologies
• Agilis Biotherapeutics
• Aldevron
• Allele Biotechnology
• Alma Bio Therapeutics
• AlphaVax
• Althea Technologies
• American Gene Technologies
• Amgen
• AMSBIO
• Amsterdam BioTherapeutics Unit (AmBTU)
• Anaeropharma Science
• Anemocyte
• apceth Biopharma
• Applied Biological Materials (ABM)
• Applied Genetic Technologies (AGTC)
• Applied Viromics
• ARCO Design/Build
• Areta International
• Asklepios BioPharmaceutical
• Atlantic Bio GMP
• ATVIO Biotech
• Audentes Therapeutics
• Autolus
• AveXis
• Avista Capital Partners
• AVROBIO
• Bamboo Therapeutics
• Batavia Biosciences
• Bavarian Nordic
• Baxter
• Beckman Research Institute
• Belfer Gene Therapy Core Facility, Cornell University
• Benitec Biopharma
• BioCancell
• Biogen
• and many more…
  

For more information about this report visit https://www.researchandmarkets.com/r/jzizha

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900